Cite
HARVARD Citation
Campone, M. et al. (2014). Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe. Journal of medical economics. pp. 837-845. [Online].